Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey.

COVID-19 COVID-19 vaccine Coronavirus Disease 2019 adverse events reactogenicity safety tolerability

Journal

Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444

Informations de publication

Date de publication:
17 Mar 2021
Historique:
received: 24 02 2021
revised: 15 03 2021
accepted: 16 03 2021
entrez: 3 4 2021
pubmed: 4 4 2021
medline: 4 4 2021
Statut: epublish

Résumé

An online survey was conducted to compare the safety, tolerability and reactogenicity of available COVID-19 vaccines in different recipient groups. This survey was launched in February 2021 and ran for 11 days. Recipients of a first COVID-19 vaccine dose ≥7 days prior to survey completion were eligible. The incidence and severity of vaccination side effects were assessed. The survey was completed by 2002 respondents of whom 26.6% had a prior COVID-19 infection. A prior COVID-19 infection was associated with an increased risk of any side effect (risk ratio 1.08, 95% confidence intervals (1.05-1.11)), fever (2.24 (1.86-2.70)), breathlessness (2.05 (1.28-3.29)), flu-like illness (1.78 (1.51-2.10)), fatigue (1.34 (1.20-1.49)) and local reactions (1.10 (1.06-1.15)). It was also associated with an increased risk of severe side effects leading to hospital care (1.56 (1.14-2.12)). While mRNA vaccines were associated with a higher incidence of any side effect (1.06 (1.01-1.11)) compared with viral vector-based vaccines, these were generally milder (

Identifiants

pubmed: 33803014
pii: life11030249
doi: 10.3390/life11030249
pmc: PMC8002738
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

BMJ. 2021 Jan 22;372:n83
pubmed: 33483336
JAMA. 2021 Mar 1;:
pubmed: 33646292
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
JAMA. 2021 Jan 12;325(2):123-124
pubmed: 33331845
N Engl J Med. 2021 Apr 8;384(14):1372-1374
pubmed: 33691060
Lancet. 2021 Dec 19;396(10267):1979-1993
pubmed: 33220855
Thorax. 2020 Dec 3;:
pubmed: 33273026
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246

Auteurs

Alexander G Mathioudakis (AG)

Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester M23 9LT, UK.
North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester M23 9LT, UK.

Murad Ghrew (M)

Department of Respiratory Medicine, Salford Royal Hospital NHS Foundation Trust, Manchester M6 8HD, UK.
Department of Intensive Care Medicine, Salford Royal Hospital NHS Foundation Trust, Manchester M6 8HD, UK.
Faculty of Biology, Medicine & Health, School of Biological Sciences, The University of Manchester, Manchester M13 9PL, UK.

Andrew Ustianowski (A)

Faculty of Biology, Medicine & Health, School of Biological Sciences, The University of Manchester, Manchester M13 9PL, UK.
Regional Infectious Diseases Unit, North Manchester General Hospital, Manchester M8 5RB, UK.

Shazaad Ahmad (S)

Department of Virology, Manchester Medical Microbiology Partnership, Manchester University NHS Foundation Trust, Manchester M13 9WL, UK.

Ray Borrow (R)

Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester M13 9WL, UK.

Lida Pieretta Papavasileiou (LP)

Department of Cardiology, Hygeia Hospital, 15123 Athens, Greece.

Dimitrios Petrakis (D)

Allergy Clinic, Petrakis Allergy Care, 55133 Thessaloniki, Greece.

Nawar Diar Bakerly (ND)

Department of Respiratory Medicine, Salford Royal Hospital NHS Foundation Trust, Manchester M6 8HD, UK.
School of Healthcare Sciences, Manchester Metropolitan University, Manchester M15 6BH, UK.

Classifications MeSH